Clarifi ASD in the news
Oral microbial activity may help identify autism in children
HELIO PSYCHIATRIC ANNALS
The Clarifi autism
Clarifi ASD is designed to provide a probability of an autism diagnosis based on epigenetic biomarkers in the saliva for children 18 months through 6 years of age.
Non-invasive and easily administered at-home saliva test
Accelerates the diagnostic process with results in 3 to 6 weeks
Based on peer-reviewed research
Measures epigenetic molecules in saliva
Is your child eligible for Clarifi ASD?
Clarifi ASD is appropriate for children who meet the following eligibility requirements.
Suspicion of autism
For children with a clinical suspicion of autism, such as a positive screen on M-CHAT-R
Appropriate age range
Must be 18 months through 6 years of age
Meets geographic requirements
Clarifi ASD will be available in the U.S.
The road to Clarifi ASD
Read about our team’s journey translating a medical discovery into an innovative clinical product.
Rising autism prevalence and
longer wait times for diagnosis
According to the CDC, 1 in 44 children in the U.S. are diagnosed with ASD. Even though ASD can be clinically diagnosed as early as 2 years, the average age of diagnosis is currently 4 years of age. A biological, diagnostic tool can further inform clinical judgment and substantially improve early identification.
Rising autism prevalence and longer wait times for diagnosis
According to the CDC, 1 in 54 children in the U.S. are diagnosed with ASD. Even though ASD can be clinically diagnosed as early as 2 years, the average age of diagnosis is currently 4 years of age. A biological, diagnostic tool can further inform clinical judgment and substantially improve early identification.
Co-CEO – Quadrant Laboratories
Cutting-edge breakthroughs in epigenetic research
Clarifi ASD is not a genetic test. It is the product of scientific advancements in the area of epigenetics; the factors that influence how genes are turned on and off. Our peer-reviewed research discovered that certain RNA molecules that regulate genetic activity and reflect interactions between a patient and their environment, were different in children with autism.
Translating the science into practical solutions
Quadrant Biosciences’ unique bioinformatics platform and CLIA-certified Laboratories facilitate the development and validation of Laboratory Developed Tests (LDTs) to turn novel discoveries into clinically available solutions.
Learn more about our science.
“A test which can separate children who have screened M-CHAT positive into high likelihood of autism or low likelihood of autism could help streamline waitlists and permit earlier diagnosis and enrollment in autism treatment.”
Dr. Daniel Coury MD
Professor of Pediatrics and Psychiatry at College of Medicine at The Ohio State University and the Section of Developmental and Behavioral Pediatrics for Nationwide Children’s Hospital
Diagnosis is only the first step
Quadrant Biosciences is proud to support Autism Speaks in providing resources and solutions to individuals and families touched by autism. In your patient account, you will find links to resources such as toolkits, local service provider directories and other helpful information.
Autism Speaks is dedicated to promoting solutions, across the spectrum and throughout the lifespan, for the needs of individuals and their families.
“As a company, we are committed to looking outside ourselves, and deploying our resources to assist other organizations and research efforts dedicated to improving the lives of people with autism and their families.”
Founder and CEO, Quadrant Biosciences
Subscribe to Clarifi ASD
Get important details in your inbox